Why the study?
Does continuous infusion of the PDE5 inhibitor UK-357,903 reduce blood pressure and alter regional haemodynamics in conscious spontaneously hypertensive rats compared to enalapril or vehicle?
Does continuous infusion of the PDE5 inhibitor UK-357,903 reduce blood pressure and alter regional haemodynamics in conscious spontaneously hypertensive rats compared to enalapril or vehicle?
The PDE5 inhibitor UK-357,903 produces transient blood pressure reductions in hypertensive rats that wane over time, likely due to compensatory mechanisms, in contrast to the sustained effects of enalapril.
Answers are grounded in this paper and cite their sources.
Transient BP effects of PDE5 inhibition in hypertensive rats caution against clinical translation; leaves open whether compensatory mechanisms limit durability versus ACE inhibitors.
Regional haemodynamic responses to a continuous, 4-day infusion of the selective phosphodiesterase type 5 inhibitor, UK-357,903 (0.133 or 1.33 mg x kg(-1) h(-1)) were measured in conscious spontaneously hypertensive rats, and compared with those of enalapril (1 mg x kg(-1) h(-1)). 2. Both doses of UK-357,903 caused modest reductions in mean blood pressure that were not dose-dependent and only significantly different from the vehicle effects on Day 1 of the study (mean -11.8 and -15.3 mmHg for low and high doses, respectively). UK-357,903 had mesenteric and hindquarters vasodilator effects, which were, again, similar for both dose levels and only significantly different from vehicle on Day 1. Neither dose of UK-357,903 affected renal vascular conductance or heart rate. 3. Although the haemodynamic effects of UK-357,903 were not clearly dose-related and some appeared to wane with time, geometric mean plasma levels of UK-357,903 increased in proportion to dose, and were sustained throughout the infusion period. Furthermore, plasma cyclic guanosine monophosphate, a biomarker of phosphodiesterase 5 inhibition, was persistently elevated, and increased with increasing dose. 4. Enalapril caused a fall in mean blood pressure on day 1 (-14.1 mmHg) that was associated with dilatation in renal, mesenteric and hindquarters vascular beds. The haemodynamic effects of enalapril were sustained or increased over the 4-day infusion, although plasma free drug levels were stable. 5. In conclusion, we have shown regional and temporal changes in the haemodynamic effects of UK-357,903, which may be due to activation of compensatory mechanisms, but there were no signs of functional compensation to the cardiovascular effects of enalapril.
No takes yet. Share an insight, caveat, or question.
Gardiner et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: